drugset
drugset / Trial / NCT05851378

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

NCT05851378 ↗

Phase 0 Completed 12 enrolled Robert Bok, MD, PhD National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.

Timeline

Start
2023-04-11
Primary completion
2026-01-31
Completion
2026-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyperpolarized Carbon 13 Alpha-ketoglutarate Unknown 0.67 ml Intravenous

Indications

glioma